Dashboard
1
With a fall in Net Sales of -4.06%, the company declared Very Negative results in Sep 25
- The company has declared negative results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Lowest at CNY 285.02 MM
- NET SALES(9M) At CNY 762.86 MM has Grown at -10.64%
- ROCE(HY) Lowest at 12.39%
2
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,809 Million (Small Cap)
19.00
NA
2.07%
-0.51
12.21%
2.76
Revenue and Profits:
Net Sales:
260 Million
(Quarterly Results - Mar 2026)
Net Profit:
33 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.31%
0%
-5.31%
6 Months
-6.47%
0%
-6.47%
1 Year
-0.99%
0%
-0.99%
2 Years
-32.89%
0%
-32.89%
3 Years
-50.15%
0%
-50.15%
4 Years
-7.59%
0%
-7.59%
5 Years
-46.75%
0%
-46.75%
Shenzhen Lifotronic Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.39%
EBIT Growth (5y)
13.69%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.52
Sales to Capital Employed (avg)
0.50
Tax Ratio
4.81%
Dividend Payout Ratio
34.97%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
30.25%
ROE (avg)
15.82%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
2.86
EV to EBIT
20.83
EV to EBITDA
17.69
EV to Capital Employed
4.86
EV to Sales
4.58
PEG Ratio
NA
Dividend Yield
2.04%
ROCE (Latest)
23.32%
ROE (Latest)
14.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
260.00
215.00
20.93%
Operating Profit (PBDIT) excl Other Income
46.40
53.40
-13.11%
Interest
0.10
0.60
-83.33%
Exceptional Items
0.00
0.50
-100.00%
Consolidate Net Profit
32.70
53.40
-38.76%
Operating Profit Margin (Excl OI)
178.40%
200.00%
-2.16%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 20.93% vs -29.67% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -38.76% vs -50.05% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,028.70
1,136.80
-9.51%
Operating Profit (PBDIT) excl Other Income
182.60
356.90
-48.84%
Interest
7.10
7.50
-5.33%
Exceptional Items
-12.40
-13.80
10.14%
Consolidate Net Profit
178.80
343.00
-47.87%
Operating Profit Margin (Excl OI)
138.40%
281.40%
-14.30%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -9.51% vs 0.13% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -47.87% vs 4.73% in Dec 2024
About Shenzhen Lifotronic Technology Co., Ltd. 
Shenzhen Lifotronic Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






